Insulin has been available to America’s diabetes patients for decades. Millions rely on this medicine every day to control their diseases and maintain their health and quality of life. The number of American’s suffering from Type I and Type II diabetes continues to rise, yet patients face increasing difficulties in paying for this life-saving medicine.
FDA-approved biosimilar medicines have the potential to make insulin more affordable and accessible to patients. However, realizing the promise of biosimilar insulins requires addressing a series of challenges that threaten their future.
This paper outlines those challenges and recommends actions for policymakers to foster the development of biosimilar insulins for America’s patients.
Click here to view the full whitepaper.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.